Kynurenic acid - CAS:492-27-3

您当前的位置：

Kynurenic acid (Synonyms:犬尿喹啉酸; Quinurenic acid)

目录号 : KM7053 CAS No. : 492-27-3

Data Sheet 产品使用指南

Kynurenic acid 是一种内源性色氨酸代谢物，是针对靶点 NMDA, glutamate, α7 nicotinic acetylcholine receptor 的广谱性拮抗剂，Kynurenic acid 也是 GPR35/CXCR8 的激动剂。

规格	价格	是否有货
100mg		In-stock
500mg		In-stock
1g	询价	In-stock
5g	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Cathepsin B, Bovine spleen In-stock
Pyridinium bisretinoid A2E In-stock
Green Tea Extract In-stock
Bleximenib In-stock
MPTP In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.

体外研究

GPR35 functions as a receptor for the kynurenine pathway intermediate kynurenic acid. Kynurenic acid elicits calcium mobilization and inositol phosphate production in a GPR35-dependent manner in the presence of G _qi/o chimeric G proteins. Kynurenic acid stimulates [S]guanosine 5′-O-(3-thiotriphosphate) binding in GPR35-expressing cells, an effect abolished by pertussis toxin treatment. Kynurenic acid also induces the internalization of GPR35. KYNA’s neuroinhibitory qualities and its neuroprotective and anticonvulsant effects are discovered using concentrations of the compound in the millimolar range. This, as well as the low affinity of KYNA at each of the three ionotropic glutamate receptors responsible for these effects [NMDA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate], together with the realization that KYNA concentrations in the mammalian brain are in the sub-micromolar range, suggested that other receptors might serve as targets of endogenous Kynurenic acid. Kynurenic acid, with a shallower inhibition curve and non-competitively, antagonizes α7nAChRs on cultured hippocampal neurons with an IC₅₀ in the low micromolar range.

体内研究

Kynurenic acid affects the activity of leukocytes in the peripheral blood of mice, although the lowest one (2.5 mg/L) has the most profound influence in contrast to the highest one (250 mg/L), which produces the weakest effect. The lowest Kynurenic acid dose stimulates the proliferative response of T lymphocytes (p<0.05), after 7 and 28 days of administering the acid to the animals.

分子式

C₁₀H₇NO₃

分子量

189.17

CAS号

492-27-3

中文名称

犬尿喹啉酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

0.1 M NaOH : 12.5 mg/mL (66.08 mM; ultrasonic and adjust pH to 9 with NaOH)

DMSO : 9 mg/mL (47.58 mM; Need ultrasonic and warming)

H2O : < 0.1 mg/mL (ultrasonic) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.2863 mL	26.4313 mL	52.8625 mL
5 mM	1.0573 mL	5.2863 mL	10.5725 mL
10 mM	0.5286 mL	2.6431 mL	5.2863 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 50% PEG300 → 50% saline

Solubility: 33.33 mg/mL (176.19 mM); Suspended solution; Need ultrasonic

2.

请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 1.25 mg/mL (6.61 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (6.61 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
3

请依序添加每种溶剂： 10% DMSO → 90% corn oil

Solubility: ≥ 1.25 mg/mL (6.61 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (6.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。